# **IMMUNOGEN**

ImmunoGen, Inc. Investor Relations Department 830 Winter Street Waltham, MA 02451 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: IMGN	
Last Trade:	5.86
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	-0.31 🖶 (-5.024%)
Day Range	5.84 - 6.21
52-Week Range	1.51 - 8.84
Volume	3,262,442

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

ImmunoGen is a clinicalstage biotechnology company that develops targeted cancer therapeutics using its proprietary antibodydrug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRαpositive platinumresistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlierstage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roc... (more)

#### **Stock Performance**



#### Press Releases [View all]

Oct 20, 2017

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial Results

Oct 16, 2017

ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active

Oct 11, 2017

ImmunoGen Announces Closing of Public
Offering of Common Stock, Including Full
Exercise of Underwriters' Option to Purchase
Additional Shares

Oct 5, 2017

ImmunoGen Announces Pricing of Public Offering of Common Stock

Oct 4, 2017

ImmunoGen Announces Proposed Public
Offering of Common Stock

### Upcoming Events [View all]

Nov 3, 2017 8:00 AM ET

3rd Quarter 2017 Operating Results Conference
Call

Nov 15, 2017 5:40 AM ET

Jefferies Global Healthcare Conference
(London)

#### Financials [View all]

Second Quarter Financial Results

Aug 25, 2016 Annual Report (10-K)

Apr 28, 2017
Proxy Statement (DEF 14A)

Aug 4, 2017

Quarterly Report (10-Q)

May 5, 2017

Quarterly Report (10-Q)

Nov 4, 2016

Quarterly Report (10-Q)